In a phase II trial, the treatment of high-dose ACC inhibitors for 12 weeks significantly reduced hepatic steatosis in patients with NASH, but elevated serum TG levels were considered likely to be due to a compensatory increase in SREBP-1C activity (Kim et al., 2017). Here, SREBF1 is linked to Hepatic steatosis.